Comparative Efficacy of Tacrolimus and Mometasone Furoate in Topical Treatment for Atopic Dermatitis: A Randomized Controlled Trial
Authors/Creators
- 1. Senior Resident, Department of Skin & VD, Darbhanga Medical College & Hospital, Leheriasarai, Bihar, India
- 2. Assistant Professor, Department of Skin & VD, Darbhanga Medical College & Hospital, Leheriasarai, Bihar, India
Description
Background: Atopic dermatitis (AD) significantly impacts patients’ quality of life due to symptoms like itchiness and skin inflammation. Tacrolimus and mometasone furoate are commonly used topical treatments for AD, each with unique benefits. While tacrolimus offers effective treatment without long-term steroid side effects, mometasone furoate provides potent anti-inflammatory effects. Comparative studies between these treatments aim to assess their efficacy and safety in managing AD. Methods: This randomized controlled trial enrolled 70 adults aged 18-65 with moderate to severe AD. Participants were randomly assigned to receive either tacrolimus 0.1% ointment or mometasone furoate 0.1% cream topically twice daily. Outcome measures included AD severity, pruritus improvement, adverse events, and quality of life. Statistical analysis determined treatment effects. Results: Both treatments significantly reduced AD severity and pruritus without significant differences between groups. Adverse events were mild and comparable. Quality of life improved similarly in both groups. Subgroup analyses showed no significant differences based on disease severity, age, or gender. Adherence to treatment was high, and both treatments were well-tolerated. Conclusion: Both tacrolimus and mometasone furoate are effective and well-tolerated treatments for AD. Clinicians can consider individual patient factors when choosing between them. Further research could explore larger-scale studies with longer follow-up to confirm these findings. Recommendations: Clinicians should consider tacrolimus and mometasone furoate as viable treatment options for AD, tailoring treatment choices to individual patient needs. Larger studies with longer follow-up could provide additional insights into treatment efficacy and safety.
Abstract (English)
Background: Atopic dermatitis (AD) significantly impacts patients’ quality of life due to symptoms like itchiness and skin inflammation. Tacrolimus and mometasone furoate are commonly used topical treatments for AD, each with unique benefits. While tacrolimus offers effective treatment without long-term steroid side effects, mometasone furoate provides potent anti-inflammatory effects. Comparative studies between these treatments aim to assess their efficacy and safety in managing AD. Methods: This randomized controlled trial enrolled 70 adults aged 18-65 with moderate to severe AD. Participants were randomly assigned to receive either tacrolimus 0.1% ointment or mometasone furoate 0.1% cream topically twice daily. Outcome measures included AD severity, pruritus improvement, adverse events, and quality of life. Statistical analysis determined treatment effects. Results: Both treatments significantly reduced AD severity and pruritus without significant differences between groups. Adverse events were mild and comparable. Quality of life improved similarly in both groups. Subgroup analyses showed no significant differences based on disease severity, age, or gender. Adherence to treatment was high, and both treatments were well-tolerated. Conclusion: Both tacrolimus and mometasone furoate are effective and well-tolerated treatments for AD. Clinicians can consider individual patient factors when choosing between them. Further research could explore larger-scale studies with longer follow-up to confirm these findings. Recommendations: Clinicians should consider tacrolimus and mometasone furoate as viable treatment options for AD, tailoring treatment choices to individual patient needs. Larger studies with longer follow-up could provide additional insights into treatment efficacy and safety.
Files
IJPCR,Vol16,Issue2,Article178.pdf
Files
(279.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:3c4dff3578b59d33e300185dbd76945e
|
279.4 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-02-20
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue2,Article178.pdf
- Development Status
- Active
References
- 1. Paller AS, Lebwohl M, Fleischer Jr AB, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52(5):810-22. 2. Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an activeand placebo-controlled study. Allergy. 1996;51 (8):569-76. 3. Beck LA. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol. 2005;53(2): S165-70. 4. Dähnhardt D, Bastian M, Dähnhardt-Pfeiffer S, et al. Comparing the effects of proactive treatment with tacrolimus ointment and mometasone furoate on the epidermal barrier structure and ceramide levels of patients with atopic dermatitis. J Dermatolog Treat. 2021;3 2(7):721- 729. 5. Lee WQ, Manogalan K, Wong PL, et al. Observational Study of the Changes in Skin Thickness Among Children with Atopic Dermatitis Treated with Topical Mometasone Furoate 0.1% Cream. J Skin Stem Cell. 2024;11 (1):e139473. 6. Yang H, Shu H, Miao L, et al. Efficacy and safety of sequential topical 0.1% mometasone furoate cream and 2% crisaborole in the treatment of mild to moderate atopic dermatitis in children aged over 2 years—a multicentre parallel randomised controlled study in China. Br J Dermatol. 2024;190(Suppl_2):ii1. 7. Dähnhardt-Pfeiffer S, Dähnhardt D, Buchner M, et al. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. J Dtsch Dermatol Ges. 2013; 11(5): 437- 443. 8. Thurka S, Chakradhar T, Fulmali S, Padmaja P. A comparative study of topical Mometasone and Tacrolimus ointment in the treatment of atopic dermatitis at Tertiary Care Centre, Telangana. Asian J Pharm Pharmacol. 2022;8 (4): 110-5.